NASDAQ:ZBIO Zenas BioPharma (ZBIO) Stock Price, News & Analysis $18.97 -0.87 (-4.39%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$19.05 +0.08 (+0.42%) As of 05/22/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zenas BioPharma Stock (NASDAQ:ZBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zenas BioPharma alerts:Sign Up Key Stats Today's Range$18.94▼$20.1650-Day Range$16.91▼$24.5052-Week Range$8.91▼$44.60Volume342,230 shsAverage Volume555,534 shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$44.29Consensus RatingModerate Buy Company Overview Zenas BioPharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns. Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. Its integrated research infrastructure encompasses medicinal chemistry, in vitro and in vivo pharmacology, as well as manufacturing capabilities to support rapid progression of lead molecules into clinical development. The company’s pipeline includes immuno-oncology candidates designed to modulate checkpoint pathways in solid tumors, alongside antiviral programs targeting broad-spectrum viral threats. Each program is engineered to combine high specificity with favorable pharmacokinetic properties, with key assets currently in IND-enabling stages and early clinical trials. To advance its programs, Zenas BioPharma collaborates with academic institutions and contract research organizations, leveraging external expertise and resources. Serving global markets, the company is committed to addressing unmet medical needs and bringing differentiated therapies to patients worldwide.AI Generated. May Contain Errors. Read More Zenas BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreZBIO MarketRank™: Zenas BioPharma scored higher than 66% of companies evaluated by MarketBeat, and ranked 283rd out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingZenas BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialZenas BioPharma has a consensus price target of $44.29, representing about 133.5% upside from its current price of $18.97.Amount of Analyst CoverageZenas BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zenas BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zenas BioPharma are expected to grow in the coming year, from ($4.47) to ($3.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zenas BioPharma is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zenas BioPharma is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZenas BioPharma has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zenas BioPharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.25% of the float of Zenas BioPharma has been sold short.Short Interest Ratio / Days to CoverZenas BioPharma has a short interest ratio ("days to cover") of 23.97, which indicates bearish sentiment.Change versus previous monthShort interest in Zenas BioPharma has recently increased by 6.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZenas BioPharma does not currently pay a dividend.Dividend GrowthZenas BioPharma does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.07 News SentimentZenas BioPharma has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Zenas BioPharma this week, compared to 6 articles on an average week.Search Interest9 people have searched for ZBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Zenas BioPharma in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $5,150,198.00 in company stock, which represents 0.4301% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Zenas BioPharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,150,198.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.00% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsZenas BioPharma has minimal institutional ownership at this time.Read more about Zenas BioPharma's insider trading history. Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZBIO Stock News HeadlinesZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 ...May 19, 2026 | markets.businessinsider.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 CongressMay 19, 2026 | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 23 at 1:00 AM | Profits Run (Ad)Zenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Purchases 60,000 SharesMay 19, 2026 | americanbankingnews.comZenas BioPharma (NASDAQ:ZBIO) CEO Purchases $1,012,800.00 in StockMay 19, 2026 | insidertrades.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comZenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS SegmentMay 18, 2026 | tipranks.comLeon Moulder, Jr. Buys 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) StockApril 30, 2026 | insidertrades.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas BioPharma's stock was trading at $36.31 at the beginning of the year. Since then, ZBIO stock has decreased by 47.8% and is now trading at $18.97. How were Zenas BioPharma's earnings last quarter? Zenas BioPharma, Inc. (NASDAQ:ZBIO) posted its quarterly earnings results on Wednesday, May, 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.01. When did Zenas BioPharma IPO? Zenas BioPharma (ZBIO) raised $225 million in an initial public offering on Thursday, September 12th 2024. The company issued 13,235,294 shares at a price of $16.00-$18.00 per share. Who are Zenas BioPharma's major shareholders? Top institutional shareholders of Zenas BioPharma include Bank of America Corp DE (0.62%), Jennison Associates LLC (0.44%), iA Global Asset Management Inc. (0.38%) and SEB Asset Management AB (0.29%). Insiders that own company stock include Fairmount Funds Management Llc, Sr One Capital Management, Llc, Jason Raleigh Nunn, Hongbo Lu, Leon O Moulder Jr, Patricia L Allen and Patrick G Enright. View institutional ownership trends. How do I buy shares of Zenas BioPharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zenas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Company Calendar Last Earnings5/13/2026Today5/23/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, ZBIO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 WebN/A Phone(857) 271-2954FaxN/AEmployeesN/AYear Founded2019Price Target and Rating Average Price Target for Zenas BioPharma$44.29 High Price Target$55.00 Low Price Target$22.00 Potential Upside/Downside+133.5%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($8.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$377.74 million Net MarginsN/A Pretax Margin-3,778.16% Return on Equity-99.99% Return on Assets-58.06% Debt Debt-to-Equity Ratio1.04 Current Ratio11.94 Quick Ratio11.94 Sales & Book Value Annual Sales$10 million Price / Sales119.76 Cash FlowN/A Price / Cash FlowN/A Book Value$5.32 per share Price / Book3.57Miscellaneous Outstanding Shares63,130,000Free Float49,244,000Market Cap$1.20 billion OptionableN/A Beta-0.61 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
